Viking offers asymmetric upside in GLP-1 drugs with positive trial data, strong cash, and buyout potential despite biotech ...

If you've ever experienced the shock and disappointment of having your lunch stolen at work, you're not alone. Here are a few ...

Discover why drug stocks like LLY, NVO, AZN & PFE could outperform in 2025 amid strong healthcare trends. Click for my picks.

Delve into Eli Lilly’s biopharma strategy as it advances its pipeline, wins regulatory milestones, and forges strategic deals ...

A CBD seltzer or THC mocktail may seem like a good alternative to alcohol but their effects are very different.

HONG KONG, Sept. 22, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that ASC47, a muscle-preserving weight loss drug candidate, in combination with semaglutide, ...

Additional Data from MAPLE-HCM Show Aficamten Significantly Improves Measures of Maximaland Submaximal Exercise Capacity and Recovery Compared to ...

Trump, rescheduling, and the future of cannabis: chaos, risk, and opportunity as operators navigate federal change, markets, ...

VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe ...

CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Acquires Portfolio of Factor XIa Inhibitors On September 15, 2025, ...

Top 10 washing machines with inbuilt heaters in Oct 2025 let you compare energy ratings, hygiene wash, hard water care, app ...

- Ultra-long-acting subcutaneous (SQ) depot formulation of ASC47 demonstrated a lower rebound effect after treatment discontinuation compared to the semaglutide monotherapy group, supporting the ...